Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Photoperiodic co-regulation of kisseptin, neurokinin B and dynorphin in the hypothalamus of a seasonal rodent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Distribution and seasonal variation in hypothalamic RF-amide peptides in a semi-desert rodent, the jerboa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mapping of kisspeptin fibres in the brain of the pro-oestrus rat

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Characterization of the uptake of DADLE to isolated nerve terminals - morphine stimulates uptake

    Publikation: Bidrag til tidsskriftKonferenceartikelForskningpeer review

Vis graf over relationer

The benefit of surgery in high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) is uncertain. The present study aimed to investigate outcomes after tumour surgery in patients with high-grade (Ki-67 > 20%) GEP NEN or MiNEN stage I-III or stage IV. We analysed data from patients treated in the period 2007-2015 at eight Nordic university hospitals. Overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS) were analysed by Kaplan-Meier estimates. Prognostic factors were evaluated using Cox regression. We included 201 surgically resected patients, 143 stage I-III and 58 stage IV, with 68% having neuroendocrine carcinoma, 23% MiNEN, 5% neuroendocrine tumour G3 and 4% uncertain NEN G3. Primary tumours were located in colon/rectum (52%), oesophagus/cardia (19%), pancreas (10%), stomach (7%), jejunum/ileum (5%), duodenum (4%), gallbladder (2%) and anal canal (1%). For patients with stage I-III, median DFS was 12 months (95% confidence interval [CI] = 5.5-18.5) and median OS was 32 months (95% CI = 24.0-40.0). For patients with stage I-III and an R0 resection, median DFS was 21 months (95% CI = 4.9-37.1) and median OS was 39 months (95% CI = 25.0-53.0). For patients with stage IV, median PFS/DFS was 4 months (95% CI = 1.9-6.1) and median OS was 11 months (95% CI = 4.8-17.2). For patients with stage IV and an R0 resection, median DFS was 6 months (95% CI = 0-16.4) and median OS was 32 months (95% CI = 25.5-38.5). Performance status > 1 and colorectal primary were associated with poor prognosis. There was no difference in survival between patients with high-grade GEP NEN and MiNEN. Surgery of the primary tumour in patients with loco-regional high-grade GEP NEN or MiNEN led to good long-term results and should be considered if an R0 resection is considered achievable. Highly selected patients with stage IV disease may also benefit from surgery.

OriginalsprogEngelsk
Artikelnummere12967
TidsskriftJournal of Neuroendocrinology
Vol/bind33
Udgave nummer5
Sider (fra-til)e12967
ISSN0953-8194
DOI
StatusUdgivet - maj 2021

Bibliografisk note

© 2021 British Society for Neuroendocrinology.

ID: 68602393